(Q38044986)

27 August 2017

Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma (English)

1 reference

27 August 2017

Paul L McCormack

1

1 reference

27 August 2017

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

72

1 reference

27 August 2017

15

1 reference

27 August 2017

2023-2032

1 reference

https://scigraph.springernature.com/pub.10.2165/11209010-000000000-00000

27 August 2017

0 references

cites work

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

The proteasome: paradigm of a self-compartmentalizing protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209010-000000000-00000

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

12 December 2020

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

1 reference

12 December 2020

Relapsed multiple myeloma

1 reference

12 December 2020

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

1 reference

12 December 2020

10.2165/11209010-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22994535

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22994535